I forlængelse af følgende melding:
March 8, 2019, Targovax granted European Patent for mutant-RAS neoantigen platform lead products
- melder selskabet i dag, at IP styrkes via TG-platformen nu også er dækket via patent på fra USPTO. Et tydeligt signal fra ledelsen om at levere på Øystein Sougs udtalelse fra Q4 rapporten om at gå efter mulig approval på “mutant ras biomarker” og “based on the data we have so far, it’s obvious that we’ll (…) continue to develop pancreas (TG-01)”
A Notice of Allowance is a document sent to a patent applicant from the United States Patent and Trademark Office (USPTO) after a patent examiner has decided to issue the requested patent. The Notice of Allowance comes after the inventor has turned in a patent application and provided all information about the invention.
… endvidere:
Since the Notice of Allowance shows the application is complete and meets all requirements, it is the final step in the long and complex patent application process. Your patent application has been fully reviewed and your invention has been given the green light for patenting.
Og værd at gentage fra Q4 rapporten:
We are looking at approximately 100 patients prior to applying for CMA
… en klinisk aftale som indikeret tidligere vil med al sandsynlighed være et setup, der hjælper selskabet til at nå dette niveau.